These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30867551)

  • 1. Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.
    Johansson J; Hirvonen J; Lovró Z; Ekblad L; Kaasinen V; Rajasilta O; Helin S; Tuisku J; Sirén S; Pennanen M; Agrawal A; Crystal R; Vainio PJ; Alho H; Scheinin M
    Neuropsychopharmacology; 2019 Aug; 44(9):1667-1673. PubMed ID: 30867551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total-body imaging of mu-opioid receptors with [
    Hsieh CJ; Hou C; Lee H; Tomita C; Schmitz A; Plakas K; Dubroff JG; Mach RH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3273-3283. PubMed ID: 38722383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys.
    Scott PJH; Koeppe RA; Shao X; Rodnick ME; Sowa AR; Henderson BD; Stauff J; Sherman PS; Arteaga J; Carlo DJ; Moss RB
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32192089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naloxone's dose-dependent displacement of [
    Kang Y; O'Conor KA; Kelleher AC; Ramsey J; Bakhoda A; Eisenberg SM; Zhao W; Stodden T; Pearson TD; Guo M; Brown N; Liow JS; Fowler JS; Kim SW; Volkow ND
    Sci Rep; 2022 Apr; 12(1):6429. PubMed ID: 35440607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.
    Saari TI; Strang J; Dale O
    Clin Pharmacokinet; 2024 Apr; 63(4):397-422. PubMed ID: 38485851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis.
    Hermann D; Hirth N; Reimold M; Batra A; Smolka MN; Hoffmann S; Kiefer F; Noori HR; Sommer WH; Reischl G; la Fougère C; Mann K; Spanagel R; Hansson AC
    Neuropsychopharmacology; 2017 Feb; 42(3):606-614. PubMed ID: 27510425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone-induced cortisol predicts mu opioid receptor binding potential in specific brain regions of healthy subjects.
    Wand GS; Weerts EM; Kuwabara H; Frost JJ; Xu X; McCaul ME
    Psychoneuroendocrinology; 2011 Nov; 36(10):1453-9. PubMed ID: 21549509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.
    Greenwald M; Johanson CE; Bueller J; Chang Y; Moody DE; Kilbourn M; Koeppe R; Zubieta JK
    Biol Psychiatry; 2007 Jan; 61(1):101-10. PubMed ID: 16950210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.
    Moss RB; Pryor MM; Baillie R; Kudrycki K; Friedrich C; Reed M; Carlo DJ
    PLoS One; 2020; 15(6):e0234683. PubMed ID: 32544184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reaching out for Sensitive Evaluation of the Mu Opioid Receptor in Vivo: Positron Emission Tomography Imaging of the Agonist [
    Rafique W; Khanapur S; Spilhaug MM; Riss PJ
    ACS Chem Neurosci; 2017 Sep; 8(9):1847-1852. PubMed ID: 28590714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects.
    Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME
    Alcohol; 2012 Sep; 46(6):511-7. PubMed ID: 22717196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain.
    Joutsa J; Karlsson HK; Majuri J; Nuutila P; Helin S; Kaasinen V; Nummenmaa L
    Psychiatry Res Neuroimaging; 2018 Jun; 276():41-45. PubMed ID: 29655552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
    Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H
    Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms.
    Nuechterlein EB; Ni L; Domino EF; Zubieta JK
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():69-77. PubMed ID: 27095017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced mu opioid receptor availability in schizophrenia revealed with [
    Ashok AH; Myers J; Reis Marques T; Rabiner EA; Howes OD
    Nat Commun; 2019 Oct; 10(1):4493. PubMed ID: 31582737
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Hiranita T; Ho NP; France CP
    J Pharmacol Exp Ther; 2024 Feb; 391(1):4-17. PubMed ID: 38409115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.